Fuel Innovation

Bispecific antibodies are formidable options for patients with persistent blood cancers, without the side effects of chemotherapy. City of Hope is exploring their use in clinical trials

Leading-edge radiotherapies hone in on a marker called CEA, which is often associated with colorectal as well as other cancers

With the help of a $12 million grant, City of Hope researchers are launching a clinical trial to test an exciting new therapy on a notoriously difficult-to-treat brain cancer

The renowned scientist is the newest addition to City of Hope’s growing commitment to stamp out type 1 diabetes, taking over the Wanek Family Project and chairing the Department of Diabetes Immunology

The best way to treat cancer is to prevent it in the first place. City of Hope Orange County is making groundbreaking strides in cancer prevention and early detection that are changing the understanding of the highly complex disease.

SB 987 expands access to specialized cancer care for Medi-Cal patients who receive a complex cancer diagnosis

A trial led by City of Hope, one of the largest cancer research and treatment organizations in the nation, contributed to the U.S. Food and Drug Administration's approval of mosunetuzumab (commercial name: Lunsumio) to treat people with relapsed or difficult-to-treat follicular lymphoma (FL) after receiving two or more standard therapies. FL is the most common indolent form of non-Hodgkin lymphoma (NHL) and is often characterized by periods of remission and relapse and poor long-term prognosis.

Lymphoma specialist Tycel Phillips, M.D., combines investigative rigor with down-to-Earth people skills